SESN2 and osteosarcoma: Tang et al. (2021) have found that osteosarcoma cell lines HOS, MG-63 and 143B treated with cisplatin, doxorubicin and methotrexate show increased expression of SESN2 that enhances autophagy and reduces the sensitivity of osteosarcoma cells to chemotherapeutic agents by inhibiting apoptosis.